Triamcinolone diacetate
As of the edition of 20 October 2026, Triamcinolone diacetate is a small molecule: marketed, first approved in 1982 (US); acts on NR3C1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1992
- Kind
- Small molecule
- Brand name
- Aristocort
- First approved
- 1 January 1982 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Sterimax; 4 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Triamcinolone diacetate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sterimax | Applicant | 1992 to now |
| Astellas | Acquired holder | 2005 to now |
| Delcor Asset | Acquired holder | 2015 to now |
| Fosun Pharma | Acquired holder | 2018 to now |
| Bristol Myers Squibb | Later holder | |
| Pfizer | Later holder |